Alvaro Köhn-Luque is an Associate Professor at the Oslo Center for Biostatistics and Epidemiology, University of Oslo, and Group Leader at the Department of Medical Genetics, Oslo University Hospital. His work bridges mathematical modeling with clinical applications, particularly in cancer research. His academic background includes a PhD in Mathematical and Computational Biology from Complutense University of Madrid (2012), preceded by multiple Master's degrees in Mathematics and Physics from Spanish universities. Dr. Köhn-Luque's research focuses on mathematical oncology , developing computational models to understand cancer dynamics and improve treatment strategies. His work spans multiscale modeling of tumor growth, personalized cancer medicine through computer simulations, and biomarker discovery using machine learning approaches. He has made significant contributions to modeling breast cancer progression and treatment response, particularly in the context of endocrine therapy and CDK4/6 inhibition. His recent publications demonstrate a strong trend toward integrating mechanistic learning approaches that combine mathematical models with machine learning techniques. This hybrid methodology allows for more accurate prediction of treatment outcomes while maintaining biological interpretability. His work frequently involves collaboration with clinical researchers to ensure models are grounded in real patient data and have direct translational potential. Computational modeling of tumor heterogeneity and drug response Development of methods for phenotypic deconvolution in cancer cell populations Integration of multi-omics data for personalized treatment prediction Application of birth-death processes to model tumor evolution Creation of user-friendly computational tools for biomedical researchers Dr. Köhn-Luque has supervised multiple PhD students including Even M Myklebust, Salim Ghannoum, and Xiaoran Lai, and has secured funding for projects including RESCUE, BigInsight, and Integreat. His research demonstrates a consistent trajectory from theoretical mathematical biology toward increasingly clinically relevant applications in personalized cancer medicine.
